Amgen appeals against PTAB Sanofi decision

12-04-2019

Amgen appeals against PTAB Sanofi decision

clu / iStockphoto.com

Amgen subsidiary Immunex has appealed against a Patent Trial and Appeal Board (PTAB) decision which invalidated a patent claiming antibodies that target human interleukin-4 receptors (IL-4R).


Amgen, Immunex, Sanofi-Aventis, Sanofi, Regeneron, PTAB, US Court of Appeals for the Federal Circuit, biologic, Dupixent, patent invalidation

LSIPR